Rigel names Alison Hannah as new Chief Medical Officer

Rigel Pharmaceuticals announced a leadership change in its top medical role.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.

Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of former CMO’s departure: June 25, 2026 Effective date of new CMO appointment: July 1, 2026 Start of industry consulting career: 2000 +1 more

4 metrics

Effective date of former CMO’s departure June 25, 2026 Date Lisa Rojkjaer ceased serving as EVP and CMO and separated

Effective date of new CMO appointment July 1, 2026 Date Alison L. Hannah’s role as EVP and CMO begins

Start of industry consulting career 2000 Year Alison L. Hannah began consulting on investigational cancer therapies

Board service start for Alison Hannah May 2021 Month and year she joined Rigel’s Board of Directors

Key Terms

Executive Vice President and Chief Medical Officer, Board of Directors, separated from the Company, Emerging growth company

4 terms

Executive Vice President and Chief Medical Officer financial

"was appointed Executive Vice President and Chief Medical Officer of the Company"

Board of Directors financial

"resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

separated from the Company financial

"ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did Rigel Pharmaceuticals (RIGL) announce?

Rigel Pharmaceuticals announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer. The company also disclosed that former Executive Vice President and Chief Medical Officer Lisa Rojkjaer, M.D. ceased serving in that role and separated from the company effective June 25, 2026.

Who is Alison L. Hannah, the new Chief Medical Officer at Rigel (RIGL)?

Alison L. Hannah, M.D. is Rigel’s new Executive Vice President and Chief Medical Officer. She has consulted for the pharmaceutical and biotechnology industry since 2000, directing development of investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.

When does Alison Hannah’s appointment as Rigel (RIGL) Chief Medical Officer become effective?

Alison L. Hannah’s appointment as Executive Vice President and Chief Medical Officer becomes effective July 1, 2026. On that same date, she resigned from Rigel’s Board of Directors, transitioning from a board role to a full-time executive leadership position overseeing the company’s medical functions.

What happened to former Rigel (RIGL) Chief Medical Officer Lisa Rojkjaer?

Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel. The company’s disclosure notes only her end of service and separation, without providing additional detail on the terms or reasons for her departure.

Does Alison Hannah remain on Rigel (RIGL)’s Board of Directors after becoming CMO?

No. In connection with her appointment as Executive Vice President and Chief Medical Officer, Alison L. Hannah, M.D. resigned from Rigel’s Board of Directors effective July 1, 2026. She had been a board member since May 2021 before moving fully into the executive management team.

What is Alison Hannah’s industry background relevant to her new Rigel (RIGL) role?

Alison L. Hannah, M.D. has extensive oncology development experience. Since 2000, she has been a consultant to pharmaceutical and biotechnology companies focusing on investigational cancer therapies, and previously held senior roles as Chief Medical Officer at CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/01/2026 - 04:11 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2026

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)


0-29889			94-3248524
(Commission File No.)			(IRS Employer Identification No.)

611 Gateway Boulevard Suite 900
South San Francisco, CA			94080
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (650) 624-1100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class

Trading

Symbol(s)

Name of Each Exchange on Which

Registered

Common Stock, par value $0.001 per share

RIGL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.

Dr. Hannah had served as a member of the Board since May 2021. Since 2000, Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry, directing the development of investigational cancer therapies. Prior to her consulting work, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc.

Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: July 1, 2026	RIGEL PHARMACEUTICALS, INC.

	By:	/s/ Raymond J. Furey
		Raymond J. Furey
		Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents